Adagene partners with Incyte for cancer drug combination study
Go back to Adagene partners with Incyte for cancer drug combination study| (NASDAQ: ADAG) | Delayed: 3.31 +0.05 (1.53%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $3.26 | 52 Week High | $ | |||
| Open | $3.28 | 52 Week Low | $ | |||
| Day High | $3.46 | P/E | N/A | |||
| Day Low | $3.16 | EPS | $ | |||
| Volume | 57,308 | |||||
| Incyte Genomics, Inc. (NASDAQ: INCY) | Delayed: 104.00 +3.36 (3.34%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $100.64 | 52 Week High | $118.49 | |||
| Open | $102.16 | 52 Week Low | $55.00 | |||
| Day High | $104.23 | P/E | N/A | |||
| Day Low | $101.51 | EPS | $-0.56 | |||
| Volume | 1,097,468 | |||||
